Geleneksel Hastalık Modifiye Edici Anti-romatizmal İlaç (DMARD) Başarısız Romatoid Artrit Hastalarında Biyolojik veya Tofasitinib Monoterapi: Cochrane Sistematik Derlemesi ve Network Meta-analizi
Cochrane Database Syst Rev 2016;11:CD012437.
Treatment options for RA patients who are MTX/DMARD incomplete responders (IR) include other DMARDs, biologics or tofacitinib (TOF). However, there is a lack of direct head-to-head comparator trials of biologics in people with RA. This review provides an update of the 2009 Cochrane overview, ‘Biologics for rheumatoid arthritis’,1 and provides comparisons and estimates for biologic or TOF monotherapy in MTX/DMARD-IR people with RA.The benefits and harms of biologic monotherapy (TNFis: adalimumab,...